European Medical Journal Hematology | |
An Overview of the EORTC-CLTG 2022 Congress | |
article | |
Nicola Humphry1  | |
[1] Nottingham | |
DOI : 10.33590/emjoncol/10045588 | |
来源: European Medical Journal | |
【 摘 要 】
This year’s European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Tumours Group (CLTG) Annual Meeting was held in Madrid, Spain. Presentations covered a broad range of topics in the field of cutaneous lymphomas, from molecular mechanisms, through diagnostics and prediction of prognosis, to skin-directed and targeted therapies, combination therapies, and patient-reported outcomes. There was an overall feeling at the EORTC-CLTG meeting that further research is needed to better define the molecular basis for the different forms of cutaneous T cell lymphoma (CTCL), which will facilitate the development of novel treatments and therapeutic drug combinations. However, it was clear that significant progress had been made in understanding the biology behind CTCL, and that a broad range of therapies are available that provide symptomatic control in many patients.
【 授权许可】
CC BY-NC
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202302050000129ZK.pdf | 662KB | download |